B
HeartBeam, Inc.
BEATCIK 0001779372NasdaqEmerging GrowthSurgical & Medical Instruments & ApparatusDelawareFY ends Dec 31
Period
FY 2025
Revenue
—
Net Income
$-21.02M
Total Assets
$5.84M
Equity
$2.60M
Shares Out
55.51M
Op. Cash Flow
$-13.99M
Business
HeartBeam is a medical technology company that develops portable ambulatory cardiac monitoring solutions. The company offers the FDA-cleared HeartBeam System, a credit card-sized cable-free 12-lead ECG device that captures heart electrical signals from three dimensions via integrated electrodes and synthesizes them into a 12-lead ECG reading reviewed by board-certified cardiologists. The company targets concierge and preventive cardiology practices in the United States for commercialization and is pursuing expanded indications for heart attack detection and AI-based screening algorithms.
Summary from 10-K filed 2026-03-12
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| General and administrative | 8 | 9 | 9 | 7 | 2 | |
| Research and development | 13 | 11 | 7 | 6 | 255,000 | |
| Total operating expenses | 21 | 20 | 15 | 13 | 2 | |
| Loss from operations | −21 | −20 | −15 | −13 | −2 | |
| Interest income | 122,000 | 446,000 | 675,000 | 66,000 | −2 | |
| Other income and expense (net) | 2,000 | −7,000 | 0 | 3,000 | 22,000 | |
| Total other income | 124,000 | 439,000 | 675,000 | 69,000 | −2 | |
| Loss before provision for income taxes | −21 | −19 | −15 | −13 | −4 | |
| Income tax provision | 0 | 0 | 0 | 0 | 0 | |
| Net Loss | −21 | −19 | −15 | −13 | −4 | |
| Net loss per share, basic (in dollars per share) | −0.62 | −0.73 | −0.72 | −1.59 | −1.03 | |
| Net loss per share, diluted (in dollars per share) | −0.62 | −0.73 | −0.72 | −1.59 | −1.03 | |
| Weighted average common shares outstanding, basic (in shares) | 34 | 27 | 20 | 8 | 4 | |
| Weighted average common shares outstanding, diluted (in shares) | 34 | 27 | 20 | 8 | 4 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 4 | 2 | 16 | 4 | 13 | |
| Prepaid expenses and other current assets | 202,000 | 393,000 | 636,000 | 445,000 | 806,000 | |
| Inventory | 103,000 | 0 | — | — | — | |
| Total Current Assets | 5 | 3 | 17 | 4 | — | |
| Property and equipment, net | 1 | 450,000 | 256,000 | 0 | — | |
| Other assets | 56,000 | 56,000 | 50,000 | 0 | — | |
| Total Assets | 6 | 3 | 17 | 4 | 14 | |
| Accounts payable (includes related party $5 and $5, respectively) | 1 | 531,000 | 556,000 | — | — | |
| Accrued expenses | 2 | 1 | 638,000 | — | — | |
| Total Liabilities | 3 | 2 | 1 | 2 | 588,000 | |
| Commitments (Note 7) | — | — | — | — | — | |
| Preferred Stock - $0.0001 par value; 10,000,000 shares authorized; 0 shares outstanding at December 31, 2025 and 2024 | 0 | 0 | 0 | 0 | 0 | |
| Common stock - $0.0001 par value; 100,000,000 shares authorized; 40,117,404 and 26,960,901 shares issued and outstanding at December 31, 2025 and 2024 | 4,000 | 3,000 | 3,000 | 1,000 | 1,000 | |
| Additional paid in capital | 80 | 58 | 53 | 25 | 23 | |
| Accumulated deficit | −77 | −56 | −37 | −22 | −9 | |
| Total Stockholders Equity | 3 | 2 | 16 | 2 | 13 | |
| Total Liabilities and Stockholders Equity | 6 | 3 | 17 | 4 | 14 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation | 40,000 | 7,000 | 0 | — | — | |
| Stock-based compensation expense | 5 | 4 | 3 | 1 | 192,000 | |
| Stock issuance for services | 226,000 | 0 | — | — | — | |
| Prepaid expenses and other current assets | 191,000 | 243,000 | −191,000 | 361,000 | −779,000 | |
| Inventory | −103,000 | 0 | — | — | — | |
| Accounts payable and accrued expenses | 2 | 428,000 | −471,000 | 2 | −357,000 | |
| Net cash used in operating activities | −14 | −14 | −12 | −10 | −3 | |
| Purchase of property and equipment | −600,000 | −201,000 | −256,000 | 0 | — | |
| Purchase of short-term investments | 4 | 0 | — | — | — | |
| Maturities of short-term investments | −4 | 0 | — | — | — | |
| Net cash used in investing activities | −600,000 | −201,000 | −256,000 | 0 | — | |
| Proceeds from exercise of stock options | 13,000 | 136,000 | 200,000 | 2,000 | 0 | |
| Net cash provided by financing activities | 17 | 866,000 | 25 | 350,000 | 16 | |
| Net increase (decrease) in cash and restricted cash | 2 | −14 | 13 | −10 | 13 | |
| Purchase of property and equipment in accounts payable | 92,000 | 0 | — | — | — | |
| Taxes paid | 0 | 0 | 0 | 0 | 0 |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro
Frequently asked questions
What is HeartBeam, Inc.'s CIK number?
HeartBeam, Inc.'s SEC CIK number is 0001779372 (1779372). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find HeartBeam, Inc.'s SEC filings?
All of HeartBeam, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.